Potential Role of GLP-1 Receptor Agonists for the Treatment of Alzheimer's Disease
DOI:
https://doi.org/10.58445/rars.3139Keywords:
Alzheimer's, GLP-1, Receptor Agonists, Aβ, T2DMAbstract
Alzheimer's Disease (AD) is currently one of the leading causes of mortality worldwide and is characterized by excessive accumulation of amyloid-β plaques, tau protein hyperphosphorylation, and chronic neuroinflammation. However, there are no effective cures or therapies for the treatment of AD. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of medication commonly used to treat type 2 diabetes and obesity, have recently emerged as novel candidates for AD therapy. Preclinical studies demonstrate that GLP-1 RAs efficiently cross the blood-brain barrier, reduce amyloid burden, attenuate neuroinflammation, and improve neuronal survival. Furthermore, early clinical studies show their potential for cognitive benefits in patients with AD. This review paper examines the molecular mechanism of GLP-1R signaling in the central nervous system and its therapeutic effects in the treatment of AD. Additionally, emerging therapeutic strategies, such as dual agonist treatments and organoids, offer potential increases in research and development speed, paving the way for promising future development of GLP-1 RAs and their translational progress into AD. Together, these findings suggest that GLP-1RAs are promising therapies for the treatment of AD in humans.
References
Baggio, L.L. and Drucker, D.J. (2014) ‘Glucagon-like peptide-1 receptors in the brain:
Controlling food intake and body weight’, Journal of Clinical Investigation. American Society for Clinical Investigation, pp. 4223–4226. Available at: https://doi.org/10.1172/JCI78371.
Cummings, J.L. et al. (2025) ‘evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease’, Alzheimer’s Research and Therapy , 17(1). Available at: https://doi.org/10.1186/s13195-024-01666-7.
Du, H. et al. (2022) ‘The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease’, Frontiers in Endocrinology. Available at: https://doi.org/10.3389/fendo.2022.1033479.
Filippatos, T.D., Panagiotopoulou, T. V. and Elisaf, M.S. (2014) ‘Adverse Effects of GLP-1 Receptor Agonists’, The review of diabetic studies : RDS, pp. 202–230. Available at: https://doi.org/10.1900/RDS.2014.11.202.
Hölscher, C. (2024) ‘Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson’s and Alzheimer’s disease clinical trials: A revolution in the making?’, Neuropharmacology. Elsevier Ltd. Available at: https://doi.org/10.1016/j.neuropharm.2024.109952.
Hui, E.K. et al. (2025) ‘Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis’, Journal of Alzheimer’s Disease. SAGE Publications Ltd, pp. 627–648. Available at: https://doi.org/10.1177/13872877251319054.
Kopp, K.O. et al. (2022) ‘Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment’, Pharmacological Research. Available at: https://doi.org/10.1016/j.phrs.2022.106550.
Mahalmani, V. et al. (2022) ‘Translational research: Bridging the gap between preclinical and clinical research’, Indian Journal of Pharmacology. Wolters Kluwer Medknow Publications, pp. 393–396. Available at: https://doi.org/10.4103/ijp.ijp_860_22.
Nauck, M.A. and Friedrich, N. (2013) ‘Do GLP-1-based therapies increase cancer risk?’, Diabetes Care, 36(SUPPL.2). Available at: https://doi.org/10.2337/dcS13-2004.
Teixeira, L.C.R., Luizon, M.R. and Gomes, K.B. (2025) ‘Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence’, Receptors, 4(1), p. 2. Available at: https://doi.org/10.3390/receptors4010002.
Weller, J. and Budson, A. (2018) ‘Current understanding of Alzheimer’s disease diagnosis and treatment’, F1000Research. F1000 Research Ltd. Available at: https://doi.org/10.12688/f1000research.14506.1.
Downloads
Posted
Categories
License
Copyright (c) 2025 Tyler Oyang
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.